Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
When you visit a new place, there’s always something unexpected waiting around the corner. Beyond famous landmarks and ...
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency’s review of Anaphylm NDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback